Sotorasib Combo Has Positive PFS Impact in KRAS G12C-Mutated CRC

Commentary
Video

Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.

Treatment with sotorasib (Lumakras) plus panitumumab (Vectibix) has conclusively demonstrated a positive progression-free survival (PFS) impact among patients with metastatic colorectal cancer (CRC) harboring KRAS G12C mutations, according to Marwan G. Fakih, MD.

Fakih spoke with CancerNetwork® following the FDA approval of sotorasib/panitumumab in KRAS G12C-mutated metastatic CRC about how data from the phase 3 CodeBreaK 300 trial (NCT05198934) support the clinical utility of this combination. He stated that the novel combination more than doubled the time to progression or death compared with the standard-of-care (SOC) options of trifluridine/tipiracil (Lonsurf) or regorafenib (Stivarga). Additionally, he highlighted a response rate with the sotorasib combination that exceeded prior expectations associated with second-line chemotherapy.

Topline data from the CodeBreaK 300 trial at the time of the FDA approval showed a median PFS of 5.6 months (95% CI, 4.2-6.3) with sotorasib/panitumumab vs 2.0 months (95% CI, 1.9-3.9) with SOC therapy (HR, 0.48; 95% CI, 0.3-0.78; P = .005). The objective response rate was 26% (95% CI, 15%-40%) vs 0% (95% CI, 0%-7%) in each respective arm.

Fakih is a professor in the Department of Medical Oncology & Therapeutics Research, associate director for Clinical Sciences, medical director of the Briskin Center for Clinical Research, division chief of GI Medical Oncology, and co-director of the Gastrointestinal Cancer Program at City of Hope Comprehensive Cancer Center in Duarte, California.

Transcript:

The sotorasib/panitumumab [combination] reflects a targeted therapy for KRAS G12C, and the CodeBreaK 300 trial shows, conclusively, the positive impact on PFS. The updated data showed a median PFS of [5.6] months, which was superior to trifluridine or regorafenib on the standard-of-care arm, which was 2 months from this study. That was the primary end point of this study, clearly more than doubling the time to progression in patients with metastatic colorectal cancer. There was a strong trend towards improvement in overall survival. The study was a small phase 3 trial, so it was not powered to statistically confirm superiority from the overall survival.

But that’s important; it means that you’re more likely to see responses. [Approximately] 30% of patients will have an objective response with this combination, which is higher than what you would expect with second-line treatment. This combination is approved in more of a third-line setting, but 30% is not a response rate we see with second-line chemotherapy in metastatic KRAS-mutated colorectal cancer, which means that this may palliate the symptoms related to metastatic disease as well. [It won’t] just prolong the time to progression [or] the PFS, but also reduce the burden of disease in patients, which ultimately has a positive impact on their longevity.

Reference

FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer. News release. FDA. January 16, 2025. Accessed February 4, 2025. https://shorturl.at/1WviB

Recent Videos
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
Experts from Sibley Memorial Hospital highlight radiation oncology technologies that have played key roles in cancer care at their institution.
Future work may focus on determining strategies for protecting the health of patients who undergo surgery during climate disasters.
Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.
Related Content